Intraoperative spillage of favorable histology wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):201-6. doi: 10.1016/j.ijrobp.2009.01.046.

Abstract

Purpose: We undertook this study to determine (1) the frequency with which spilled tumor cells of favorable histology produced intra-abdominal disease in patients treated with differing chemotherapy regimens and abdominal radiation therapy (RT) and (2) the patterns of relapse and outcomes in such patients.

Methods and materials: The influence of RT dose (0, 10, and 20 Gy), RT fields (flank, whole abdomen), and chemotherapy with dactinomycin and vincristine (2 drugs) vs. added doxorubicin (three drugs) on intra-abdominal tumor recurrence rates was analyzed by logistic regression in 450 patients. Each patient was considered at risk for two types of failure: flank and subdiaphragmatic beyond-flank recurrence, with the correlation between the two outcomes accounted for in the analyses.

Results: The crude odds ratio for the risk of recurrence relative to no RT was 0.35 (0.15-0.78) for 10Gy and 0.08 (0.01-0.58) for 20Gy. The odds ratio for the risk of recurrence for doxorubicin to two drugs after adjusting for RT was not significant. For Stage II patients (NWTS-4), the 8-year event rates with and without spillage, respectively, were 79% and 87% for relapse-free survival (p = 0.07) and 90% and 95% for overall survival (p = 0.04).

Conclusions: Irradiation (10 Gy or 20 Gy) reduced abdominal tumor recurrence rates after tumor spillage. Tumor spillage in Stage II patients reduced relapse-free survival and overall survival, but only the latter was of statistical significance. These data provide a basis for assessing the risks vs. benefits when considering treatment for children with favorable histology Wilms tumor and surgical spillage.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Abdominal Neoplasms / prevention & control*
  • Abdominal Neoplasms / secondary*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Dactinomycin / administration & dosage
  • Doxorubicin / administration & dosage
  • Follow-Up Studies
  • Humans
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / pathology
  • Kidney Neoplasms* / radiotherapy
  • Logistic Models
  • Neoplasm Seeding*
  • Neoplasm Staging
  • Odds Ratio
  • Peritoneal Neoplasms / prevention & control
  • Peritoneal Neoplasms / secondary
  • Radiotherapy Dosage
  • Risk Assessment / methods
  • Vincristine / administration & dosage
  • Wilms Tumor / drug therapy
  • Wilms Tumor / radiotherapy
  • Wilms Tumor / secondary*

Substances

  • Dactinomycin
  • Vincristine
  • Doxorubicin